Darlene Dobkowski, Managing Editor for CURE® magazine, has been with the team since October 2020 and has covered health care in other specialties before joining MJH Life Sciences. She graduated from Emerson College with a Master’s degree in print and multimedia journalism. In her free time, she enjoys buying stuff she doesn’t need from flea markets, taking her dog everywhere and scoffing at decaf.
Teaching Children — and the World — to Use Breathing Techniques for Cancer-Related Pain
February 2nd 2023In this episode of the “Cancer Horizons” podcast, “Rabbi G” discusses his global travels to teach breathwork to children with cancer, and gives an exercise listeners can use to decrease their pain and anxiety.
Read More
Taking 8-Plus Medications Before Cancer Treatment May Affect Effectiveness in Older Patients
February 1st 2023Older patients with advanced cancer who were taking eight or more medications before starting treatment were more likely to discontinue treatment and/or experience a side effect from drug interactions.
Read More
Phase 3 Trial in Prostate Cancer Subset Discontinued Due to Lack of Survival Benefit
January 26th 2023A data monitoring committee recommended to stop the phase 3 trial in metastatic hormone-sensitive prostate cancer due to a lack of progression-free survival and overall survival with combination therapy.
Read More
Immunotherapy Plus Chemo Boosts Event-Free Survival in Resectable Lung Cancer
January 18th 2023Patients with operable non-small cell lung cancer who were treated with an anti-PD-1 monoclonal antibody plus a doublet chemotherapy regiment did not experience cancer recurrence or new symptom onset during follow-up in a recent study.
Read More
Beta-Blockers May Improve Post-Surgical Survival in Women With Ovarian Cancer, Heart Conditions
January 18th 2023Women who were taking beta-blockers, a medicine to treat heart conditions like high blood pressure, among others, near the time of surgery for epithelial ovarian cancer may confer a survival benefit years after undergoing a procedure.
Read More
Injection Treatment for Rare Leukemia Subtype to Be Discontinued in the U.S.
January 13th 2023The injection Lumoxiti, which was approved for patients with relapsed or refractory hairy cell leukemia, will be pulled from the U.S. market later this year, although alternative therapies are available.
Read More
Chemo-Related Hearing Loss May Have Emotional, Social Impacts in Testicular Cancer Survivors
January 12th 2023Testicular cancer survivors who were treated with cisplatin-based chemotherapy may have hearing loss or ringing of the ears, which may significantly affect certain parts of life including sleep and concentration, among other factors.
Read More
Three-Drug Regimen After Transplant May Improve Relapse-Free Survival in GVHD
December 19th 2022Adults with graft-versus-host disease who were treated with a three-drug regimen with cyclophosphamide after transplant may have improved survival rate compared with those treated with a two-drug regimen.
Read More
FDA Approves First Gene Therapy for Non-Muscle Invasive Bladder Cancer
December 16th 2022Adstiladrin represents the first gene therapy approved by the FDA for the treatment of patients with high-risk non-muscle invasive bladder cancer who are resistant to BCG, the first-line standard of care for these patients.
Read More